Neutrophil-lymphocyte ratio in Crohn's disease patients predicts sustained response to infliximab 52-week therapy

J Gastrointestin Liver Dis. 2015 Mar;24(1):127-8.

Authors

Marcin K Wlodarczyk¹, Aleksandra E Sobolewska², Krystyna Stec-Michalska², Jakub J Fichna³, Maria E Wisniewska-Jarosinska²

Affiliations

¹ Department of Gastroenterology, Medical University of Lodz, Lodz, Poland. [email protected].
² Department of Gastroenterology, Medical University of Lodz, Lodz, Poland.
³ Department of Biochemistry, Medical University of Lodz, Lodz, Poland.

PMID: 25822447

No abstract available

Publication types

Letter

MeSH terms

Crohn Disease / blood
Crohn Disease / diagnosis
Crohn Disease / drug therapy*
Crohn Disease / immunology
Humans
Immunosuppressive Agents / therapeutic use*
Infliximab / therapeutic use*
Lymphocyte Count
Lymphocytes / drug effects*
Lymphocytes / immunology
Neutrophils / drug effects*
Neutrophils / immunology
Retrospective Studies
Time Factors
Treatment Outcome

Substances

Immunosuppressive Agents
Infliximab